259 results on '"Lønning, P. E."'
Search Results
2. Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
3. C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer
4. A national precision cancer medicine implementation initiative for Norway
5. Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer
6. Assessment of tumor suppressor promoter methylation in healthy individuals
7. Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES
8. Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC
9. NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients
10. Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)—first results from PathIES†
11. Vascular proliferation is a prognostic factor in breast cancer
12. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia
13. The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling
14. Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique
15. Breast cancer prognostication and prediction: are we making progress?
16. Mutation of GATA3 in human breast tumors
17. Clinical Pharmacokinetics of Aromatase Inhibitors and Inactivators
18. Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers
19. The role of aromatase inactivators in the treatment of breast cancer
20. Aromatase Inhibitors and Inactivators for Breast Cancer Therapy
21. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy
22. Molecular portraits of human breast tumours
23. Is There a Growing Role for Endocrine Therapy in the Treatment of Breast Cancer?
24. Genetic variants of CYP19 (aromatase) and breast cancer risk
25. RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer†
26. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum
27. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer
28. Pharmacological and clinical profile of anastrozole
29. Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer
30. Breast cancer prognostication and prediction in the postgenomic era
31. Paclitaxel and Docetaxel: Innovation, But at What Cost?
32. Plasma changes in breast cancer patients during endocrine therapy — lipid measurements and nuclear magnetic resonance (NMR) spectroscopy
33. Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique
34. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2–3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer
35. Aromatase Inhibitors in Malignant Diseases of Aging
36. Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment
37. Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer
38. Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer
39. The Insulin-Like Growth Factor System in Human Immunodeficiency Virus Infection: Relations to Immunological Parameters, Disease Progression, and Antiretroviral Therapy*
40. Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy
41. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study
42. Expression of full-length p53 and its isoform Δp53 in breast carcinomas in relation to mutation status and clinical parameters
43. Exemestane: A Viewpoint by Per E. Lønning
44. Single-Dose and Steady-State Pharmacokinetics of Aminoglutethimide
45. Mechanisms of Action of Aminoglutethimide as Endocrine Therapy of Breast Cancer
46. Megestrol acetate versus aminoglutethimide for metastatic breast cancer
47. The influence of a graded dose schedule of aminoglutethimide on the disposition of the optical enantiomers of warfarin in patients with breast cancer
48. Alterations in the Metabolism of Oestrogens During Treatment with Aminoglutethimide in Breast Cancer Patients: Preliminary Findings
49. Patterns of genomic evolution in advanced melanoma.
50. Long-Term Follow-Up of the Intergroup Exemestane Study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.